Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Pharma
Keytruda-Lynparza combo scores tepid win in ovarian cancer trial
After flunking three clinical trials with a Keytruda-Lynparza combo, Merck has emerged with a tepid win for the regimen in an ovarian cancer study.
Kevin Dunleavy
Dec 9, 2024 11:18am
FDA expands label for AZ's Tagrisso in NSCLC indication
Sep 26, 2024 10:52am
J&J earns 3rd NSCLC nod in 7 months for surging Rybrevant
Sep 20, 2024 11:00am
ESMO: BMS moves Opdualag into phase 3 trials in 1L NSCLC
Sep 14, 2024 2:40am
Gilead unfolds Trodelvy triplet's first-line NSCLC data
Sep 9, 2024 1:45pm
Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study
Sep 8, 2024 11:30am
